Compare IKT & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | MPAA |
|---|---|---|
| Founded | 2008 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 253.7M |
| IPO Year | 2020 | 2007 |
| Metric | IKT | MPAA |
|---|---|---|
| Price | $2.30 | $10.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $5.00 | ★ $17.50 |
| AVG Volume (30 Days) | ★ 360.8K | 100.2K |
| Earning Date | 03-26-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.76 | ★ 162.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,806,000.00 |
| Revenue This Year | N/A | $1.50 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 4.28 |
| 52 Week Low | $1.33 | $9.29 |
| 52 Week High | $2.61 | $18.12 |
| Indicator | IKT | MPAA |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 29.21 |
| Support Level | $2.29 | $9.95 |
| Resistance Level | $2.56 | $10.95 |
| Average True Range (ATR) | 0.10 | 0.39 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 20.28 | 5.90 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts, test solutions, and diagnostic equipment. Its replacement parts are mainly sold to automotive retail chain stores, warehouse distributors across North America, and automobile manufacturers for aftermarket and warranty replacement programs. The Company's test solutions and diagnostic equipment serve the automotive component and powertrain testing market. Its product portfolio includes rotating electrical products such as alternators and starters; brake-related products including brake calipers, brake rotors, brake pads, brake master cylinders, and wheel hub assemblies and bearings; and other products. Its segments are Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty.